On Thursday, RAPT Therapeutics Inc. RAPT introduced that it has determined to shut and unblind each its Part 2b trial of zelnecirnon (RPT193) in atopic dermatitis (AD) and its Part 2a trial of zelnecirnon in bronchial asthma.
Each medical trials had been positioned on medical maintain by the FDA in February 2024 based mostly on a critical hostile occasion of liver failure requiring a transplant in a single affected person within the AD trial.
Earlier than the medical maintain was imposed, 229 sufferers had been enrolled within the Part 2b AD trial, of which roughly 110 had accomplished the 16-week dosing interval.
“Though there have been a big variety of sufferers who had been unable to finish the AD trial because of the maintain, we consider we could have enough knowledge, even when not statistically vital, to tell our path ahead and assist our discussions with the FDA,” mentioned Brian Wong, President and CEO.
“We’re working with the medical trial websites to scrub the information, and we anticipate that our evaluation of the information shall be accomplished within the third quarter of this yr. Concurrently, we’re persevering with our investigation and evaluation of the intense hostile occasion that triggered the medical maintain,” the corporate added.
The corporate reported first-quarter internet lack of 2024 was $30.5 million, in comparison with $29.3 million for the primary quarter of 2023.
As of March 31, 2024, the corporate had money and money equivalents and marketable securities of $141.6 million.
Value Motion: RAPT shares are down 42.60% at $4.58 finally examine Thursday.
Photograph by Louis Reed by way of Unsplash
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
